57.72USD-3.56%Mkt Cap: —P/E: —1d ago
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selectiv…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value1.70B $
Revenue (TTM)232.39M $
Gross Profit103.61M $
Net Income (TTM)-26.79M $
Revenue/Share8.220 USD
Last Price57.72 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS0327241065
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA41.21
EV/Revenue7.33
P/S—
P/B134.58
EPS (TTM)-2.76
EPS (Forward)—
52W Range
57.720% of range61.49
52W High61.49 USD
52W Low57.72 USD
Profitability
Gross Margin44.58%
Oper. Margin-135.53%
EBITDA Margin17.79%
Profit Margin-11.53%
ROE-114.55%
ROA6.78%
Growth
Revenue Growth-8.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF4.48M $
CapEx (TTM)—
FCF Margin3.58%
FCF Yield—
Net Debt-9.10M $
Net Debt/EBITDA-0.22
Balance Sheet
Debt/Equity2175.84
Current Ratio7.58
Quick Ratio7.49
Book Value/Sh0.4390 USD
Cash/Share9.844 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.26.75M
Float19.79M
Insiders5.68%
Institutions106.04%
Technical
SMA 5021.59 (+167.3%)
SMA 20021.15 (+172.9%)
Beta0.40
S&P 52W Chg20.80%
Avg Vol (30d)404
Avg Vol (10d)186
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—